Oral bisphosphonates and osteonecrosis of the jaw

General Dentistry

Volumn 55, Issue 1, 2007, Pages 8-10

  Wynn, Richard L ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE NECROSIS; CHEMICALLY INDUCED DISORDER; HUMAN; JAW DISEASE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; RISK FACTOR; SHORT SURVEY;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS; RISK FACTORS;

EID: 33846643162     PISSN: 03636771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Marx RE. Pamidronate (Aredia) and zoledronic acid (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
3. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:135.
4. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone(osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
5. Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaw: A review of current knowledge. J Am Dental Assoc 2005;136:1669-1674.
6. Melo MD, Obeid G. Osteonecrosis of the jaw in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc 2005;136:1675-1681.
7. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
8. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
9. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003;48:268.
10. Woo SB, Hellstein JW, Kalmar JR. Narrative review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761.
11. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy-Expert panel recommendations. J Am Dent Assoc 2006;137:1144-1150.
12. Bone-building drugs: New risk explained. Consumer Reports Health 2006;March 6:3.
13. Fosamax [package insert]. Whitehouse, NJ: Merck & Co, Inc.; Feburary 2006.
14. Boniva [package insert]. Nutley, NJ: Roche Laboratories;August 2006.
15. Actonel [package insert]. Cincinnati, OH: Proctor & Gamble;August 2006.
16. Didronel [package insert]. Cincinnati, OH: P & G Pharmaceuticals; 2006.
17. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21:349-353.